Patent Assignment
Reel/Frame 061803/0878
Security Interest
Recorded: 2022-10-28
Pages: 20
Assignor
PTC THERAPEUTICS, INC.
Executed: 2022-10-27
Assignee
WILMINGTON TRUST, NATIONAL ASSOCIATION
300 S WACKER DRIVE, SUITE 1850, CHICAGO, ILLINOIS, 60606
Covered Properties
(81)
Methods for Identifying Small Molecules That Modulate Premature Translation Termination and Nonsense Mrna Decay
Methods for Identifying Small Molecules That Modulate Premature Translation Termination and Nonsense Mediated Mrna Decay
Identifying Therapeutic Compounds Based on Their Physical-Chemical Properties
1,2,4-Oxadiazole Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
1,2,4-Oxadiazole Benzoic Acid Compounds and Their Use for Nonsense Suppression and the Treatment of Disease
Benzoic Acid or Benzoate Substituted 1,2,4-Oxadiazole Compounds and Their Use for the Treatment of Disease
3-[5-(2-Fluoro-Phenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid, Compositions, and Methods for the Use Thereof
Substituted 1,2,4-Oxadiazoles, Compositions and Methods of Use
Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
1,2,4-Oxadiazole Benzoic Acid Compositions and Their Use in Bioassays
Processes for the Preparation of 1,2,4-Oxadiazole Benzoic Acids
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
Methods for Dosing an Orally Active 1,2,4-Oxadiazole
Methods for dosing an orally active 1,2,4-oxadiazole
Process for the Production of Alpha-Tocotrienol and Derivatives
Processes for the Preparation of 1,2,4-Oxadiazole Benzoic Acids
Methods for the Synthesis of 1,2,4-Oxadiazole Benzoic Acid Compounds
1,2,4-Oxadiazole Benzoic Acid Compositions and Their Use in Bioassays
Pharmaceutical Compositions of 1,2,4-Oxadiazole Benzoic Acid and Their Use for the Treatment of Disease
Redox-Active Therapeutics for Treatment of Mitochondrial Diseases and Other Conditions and Modulation of Energy Biomarkers
(Het)Aryl-P-Quinone Derivatives for Treatment of Mitochondrial Diseases
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
2-Substituted-P-Quinone Derivatives for Treatment of Oxidative Stress Diseases
Treatment of Oxidative Stress Disorders Including Contrast Nephropathy, Radiation Damage and Disruptions in the Function of Red Cells
1,2,4-Oxadiazole Benzoic Acid Compositions
Process for the Production of Alpha-Tocotrienol and Derivatives
1,2,4-Oxadiazole Benzoic Acid Compositions and Their Use in Bioassays
1,2,4-Oxadiazole Benzoic Acids
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
Treatment of Leber's Hereditary Optic Neuropathy and Dominant Optic Atrophy with Tocotrienol Quinones
Methods for Using 1,2,4-Oxadiazole Benzoic Acid Compounds
Process for the Production of Alpha-Tocotrienol and Derivatives
Application:
14/038,675 →
Publication:
US 2014/0221674
Catechol Derivatives for Treatment of Oxidative Stress Diseases
Compositions for an Orally Active 1,2,4-Oxadiazole for the Treatment of Disease
2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
2-Heterocyclylaminoalkyl-(P-Quinone) Derivatives for Treatment of Oxidative Stress Diseases
Methods for Oxidation of Alpha Tocotrienol in the Presence of Non-Alpha Tocotrienols
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid
Methods for Using 1,2,4-Oxadiazole Benzoic Acid Compounds
Compositions of 1,2,4-Oxadiazole Benzoic Acid Compounds and Methods for Their Use
Alkyl-Heteroaryl Substituted Quinone Derivatives for Treatment of Oxidative Stress Disorders
Methods for Oxidation of Alpha Tocotrienol in the Presence of Non-Alpha Tocotrienols
Compositions of 1,2,4-Oxadiazole Benzoic Acid Compounds and Methods for Their Use
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Process for the Production of Alpha-Tocotrienol and Derivatives
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid for the Treatment of Disease
Pharmaceutical Compositions and Salts of a 1,2,4-Oxadiazole Benzoic Acid
Treatment of Leber's Hereditary Optic Neuropathy and Dominant Optic Atrophy with Tocotrienol Quinones
Compositions for an Orally Active 1,2,4-Oxadiazole for the Treatment of Disease
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Methods for Selective Oxidation of Alpha Tocotrienol in the Presence of Non-Alpha Tocotrienols
Methods of Administering Deflazacort Therapy
Patent:
11,083,737 →
Application:
15/607,130 →
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Methods for Treating Epilepsy
Hydrogen Isotope-Enriched Analogues of 1,2,4-Oxadiazole Benzoic Acid Compounds, Compositions and Uses Thereof
Application:
15/776,343 →
Publication:
US 2020/0262800
Compositions of 1,2,4-Oxadiazole Benzoic Acid Compounds and Methods for Their Use
Pharmaceutical Compositions and Salts of a 1,2,4-Oxadiazole Benzoic Acid
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid for the Treatment of Disease
Compositions for an Orally Active 1,2,4-Oxadiazole for the Treatment of Disease
Methods for Selective Oxidation of Alpha Tocotrienol in the Presence of Non-Alpha Tocotrienols
Improved Methods for Enriching Alpha-Tocotrienol from Mixed Tocol Compositions
Fluoroalkyl, Fluoroalkoxy, Phenoxy, Heteroaryloxy, Alkoxy, and Amine 1,4-Benzoquinone Derivatives for Treatment of Oxidative Stress Disorders
Process for the Production of Alpha-Tocotrienol and Derivatives
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Pharmaceutical Compositions and Salts of a 1,2,4-Oxadiazole Benzoic Acid
Compositions for an Orally Active 1,2,4-Oxadiazole for the Treatment of Disease
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid for the Treatment of Disease
Compositions for an Orally Active 1,2,4-Oxadiazole for the Treatment of Disease
Fluoroalkyl, Fluoroalkoxy, Phenoxy, Heteroaryloxy, Alkoxy, and Amine 1,4-Benzoquinone Derivatives for Treatment of Oxidative Stress Disorders
Methods for Enriching Alpha-Tocotrienol from Mixed Tocol Compositions
Methods for Dosing an Orally Active 1,2,4-Oxadiazole for Nonsense Mutation Suppression Therapy
Application:
17/078,092 →
Publication:
US 2021/0038572
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid for the Treatment of Disease
Application:
17/183,342 →
Publication:
US 2021/0330647
Treatment of Oxidative Stress Disorders Including Contrast Nephropathy, Radiation Damage and Disruptions in the Function of Red Cells
Application:
17/216,502 →
Publication:
US 2021/0322337
Redox-Active Therapeutics for Treatment of Mitochondrial Diseases and Other Conditions and Modulation of Energy Biomarkers
Application:
17/334,601 →
Publication:
US 2022/0055975
Methods of Administering Deflazacort Therapy
Application:
17/394,039 →
Publication:
US 2021/0361676
Treatment of Leigh Syndrome and Leigh-Like Syndrome with Tocotrienol Quinones
Application:
17/400,028 →
Publication:
US 2022/0133648
Crystalline Forms of 3-[5-(2-Fluorophenyl)-[1,2,4]Oxadiazol-3-Yl]-Benzoic Acid for the Treatment of Disease
Application:
17/490,725 →
Publication:
US 2022/0023268
Methods for Enriching Alpha-Tocotrienol from Mixed Tocol Compositions
Method for Treating Nonsense Mutation Mediated Duchenne Muscular Dystrophy in Pediatric Patients
Process for the Production of Alpha-Tocotrienol and Derivatives
Application:
17/699,061 →
Publication:
US 2022/0204469
Related Assignments
(15)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 30, 2009
From: WESSON, KIERON E.; HINMAN, ANDREW W.; JANKOWSKI, ORION D.
To: EDISON PHARMACEUTICALS, INC.
Reel/Frame 023721/0621 →
Confirmatory Grant of Security Interest in United States Patents (Exclusively Licensed Patents)
Dec 30, 2010
From: PENWEST PHARMACEUTICALS CO.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025572/0731 →
Release of Security Interest in Exclusively Licensed Patents Recorded at Reel/Frame 25572/731
Jul 11, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: PENWEST PHARMACEUTICALS CO.
Reel/Frame 026571/0792 →
Assignment of Assignor's Interest
Mar 1, 2012
From: EDISON PHARMACEUTICALS, INC.
To: AMPERE LIFE SCIENCES, INC.
Reel/Frame 027792/0432 →
Assignment of Assignor's Interest
Sep 3, 2015
From: AMPERE LIFE SCIENCES, INC.
To: EDISON PHARMACEUTICALS, INC.
Reel/Frame 036491/0693 →
Change of Name
Feb 8, 2017
From: EDISON PHARMACEUTICALS, INC.
To: BIOELECTRON TECHNOLOGY CORPORATION
Reel/Frame 041660/0644 →
Security Interest
May 8, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 042418/0774 →
Assignment of Assignor's Interest
Jul 31, 2017
From: MOON, YOUNG-CHOON
To: PTC THERAPEUTICS, INC.
Reel/Frame 043141/0296 →
Assignment of Assignor's Interest
Jul 31, 2017
From: KARP, GARY MITCHELL; HWANG, SEONGWOO; CHEN, GUANGMING; ALMSTEAD, NEIL GREGORY
To: PTC THERAPEUTICS, INC.
Reel/Frame 043141/0219 →
Assignment of Assignor's Interest
Jul 31, 2017
From: ALMSTEAD, NEIL G.; HWANG, PETER SEONGWOO; PINES, SEEMON; MOON, YOUNG-CHOON
To: PTC THERAPEUTICS, INC.
Reel/Frame 043141/0489 →
Corrective Assignment to Correct the Inclusion of 6420591,6583309,6503713, 5843995,7029846,7056656, 6468969,6486305,6630294, 6989256,6627398,8247167, 9017935 Previously Recorded on Reel 042418 Frame 0774. Assignor(S) Hereby Confirms the Security Interest.
Aug 24, 2017
From: PTC THERAPEUTICS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 043672/0096 →
Assignment of Assignor's Interest
Nov 15, 2019
From: BIOELECTRON TECHNOLOGY CORPORATION
To: PTC THERAPEUTICS, INC.
Reel/Frame 051041/0478 →
Assignment of Assignor's Interest
Jul 14, 2020
From: BIOELECTRON TECHNOLOGY CORPORATION
To: PTC THERAPEUTICS, INC.
Reel/Frame 053210/0036 →
Release of Security Interest
Jul 14, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: PTC THERAPEUTICS, INC.
Reel/Frame 053209/0872 →
Termination and Release of Patent Security Agreement @ Reel 061803 and Frame 0878
Oct 20, 2023
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: PTC THERAPEUTICS, INC.
Reel/Frame 065303/0163 →